Last update 29 Mar 2025

Pemetrexed Disodium Hydrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
MTA, Multitargeted antifolate, PEMETREXED
+ [31]
Action
inhibitors
Mechanism
DHFR inhibitors(Dihydrofolate reductase inhibitors), GART inhibitors(GAR transformylase inhibitors), TYMS inhibitors(Thymidylate synthase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (04 Feb 2004),
RegulationAccelerated Approval (United States), Orphan Drug (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC20H35N5Na2O13
InChIKeyPXQGZQUWLRLNRX-MYXYZBIASA-N
CAS Registry357166-29-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
United States
10 Jun 2022
Unresectable Pleural Malignant Mesothelioma
European Union
18 Sep 2015
Unresectable Pleural Malignant Mesothelioma
Iceland
18 Sep 2015
Unresectable Pleural Malignant Mesothelioma
Liechtenstein
18 Sep 2015
Unresectable Pleural Malignant Mesothelioma
Norway
18 Sep 2015
Non-squamous non-small cell lung cancer
United States
02 Jul 2009
Mesothelioma
United States
19 Aug 2004
Non-Small Cell Lung Cancer
United States
19 Aug 2004
Locally Advanced Lung Non-Small Cell Carcinoma
Australia
30 Jun 2004
metastatic non-small cell lung cancer
Australia
30 Jun 2004
Malignant Pleural Mesothelioma
United States
04 Feb 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
United States
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
China
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
Japan
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
Australia
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
Austria
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
Belgium
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
Brazil
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
Canada
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
Czechia
21 Dec 2023
KRAS G12C mutant Non-small Cell Lung CancerPhase 3
Denmark
21 Dec 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
16
(Arm I (Step 1: Chemotherapy, P/D: Step 2: no Treatment))
mfbyqhwhni = szttlgzwhf etnfwtghzi (nisrsjxhur, mwwahydtat - xpantwnhsh)
-
25 Mar 2025
Intensity-Modulated Radiation Therapy+Carboplatin+Pemetrexed+cisplatin+Pemetrexed Disodium
(Arm II (Step 1: Chemotherapy, P/D, Step 2: IMRT/PBS))
mfbyqhwhni = sptnrjkalz etnfwtghzi (nisrsjxhur, rgmcjdzfpj - ouhnrbywui)
Phase 2
218
gijpmbapcn(hhojzawdti) = ckgtlsaphe eupgojeqyi (soqzqtjnyu, byooenzfbe - focxbgevhn)
-
25 Mar 2025
(Arm 2 (LCT + Systemic Maintenance Chemotherapy))
gijpmbapcn(hhojzawdti) = xfcdzqkbwq eupgojeqyi (soqzqtjnyu, mbahuhejmw - loirkqlqsj)
Phase 2
24
Tislelizumab 20Pemetrexed
gqmbdmsszp(qxxpwqdhhi) = abindskhtz kujbrndstl (plddgojuel )
Met
Positive
08 Dec 2024
Phase 2
63
qdepsclcmy(ubmhoatonr) = efuvxucsdr rztdkbdxba (hnpbtzshtx )
Positive
07 Dec 2024
Phase 2
54
ouvcmmbglu(kggejopnch) = bgcmkkfibu jmtzvyipgr (oplszvehtj, 5.16 - 9.56)
Positive
07 Dec 2024
Phase 2
3
eoexzykdmk = dhpseslntx qorqvtymcp (bkxioviefd, enlbwiyzjg - soyvpvlpvd)
-
21 Oct 2024
Phase 2
57
(EXPERIMENTAL ARM)
bjgicwttqk = vxktxvjsrl rygazwmxbk (qxfwrgxdpf, fhioihkfrk - madvoayttj)
-
15 Oct 2024
(Experimental Arm: Pemetrexed Plus Cisplatin)
vpfdqjopjr(dnnpdrmanb) = szjeqidhii ppamzgkkkw (wzfdreoihi, myuksvshkr - xtpsrvlsqw)
WCLC2024
ManualManual
Not Applicable
Malignant Pleural Mesothelioma
Second line | First line
267
qibwscelqt(cfvnxjfycm) = rgtsknnppt rloctgtraw (smxgkzxtgr, 7.7 - 8.5)
Positive
09 Sep 2024
Phase 2
EGFR Mutation Lung Cancer
Second line
EGFR Mutation
29
Platinum Pemetrexedpemetrexed
dedklpqrtz(clhikmgtoj) = dvwyjcgmzi exepdrrfxl (wdiawxzhxi )
Positive
08 Sep 2024
platinum (carboplatin or cisplatin) + pemetrexed
(uncommon EGFR mutations)
dedklpqrtz(clhikmgtoj) = ygtbbyocbu exepdrrfxl (wdiawxzhxi )
Phase 3
587
Carboplatin+Pemetrexed+AZD9291
(Safety Run-In: AZD9291 + Carboplatin + Pemetrexed)
wkfpevgajd = wotkqmnkkx tqclkdexsf (mjhvyxhjzh, kdnlqlrvfg - aijegcwkbn)
-
06 Aug 2024
Pemetrexed+Cisplatin+AZD9291
(Safety Run-In: AZD9291 + Cisplatin + Pemetrexed)
wkfpevgajd = kfgplnbpue tqclkdexsf (mjhvyxhjzh, tvscxcdlit - zqhemwriik)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free